IP Library Granted Patent US 10,828,269
Granted Patent B2
US 10,828,269 · App. 14/526,880 · Granted Nov 10, 2020

Reducing muscle atrophy by administering astaxanthin

Inventors: Yuji Naito (Shiga, JP); Jiro Takahashi (Toyama, JP); Wataru Aoi (Kyoto, JP)
Assignee: FUJI CHEMICAL INDUSTRIES CO., LTD.
A61K31/122A23L2/52A23L33/10A23L33/105A61K31/21A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,828,269
App. No.
14/526,880
Granted
Nov 10, 2020
Kind
B2
Abstract

An object of the invention is to provide a gene expression regulating agent which includes astaxanthin and/or its ester as an effective ingredient; and a food and drink having an effect of regulating gene expression which includes astaxanthin and/or its ester. Abnormal gene expression due to, for example, oxidative stress can be treated, improved, and/or prevented, and diseases caused by the abnormal gene expression can be treated, improved, and/or prevented. A gene expression regulating agent which includes astaxanthin and/or its ester as an effective ingredient; and a food and drink having an effect of regulating gene expression which includes astaxanthin and/or its ester are provided and are useful for treating, improving, and/or preventing the symptom caused by the abnormal gene expression, that is, excessive expression or suppression of expression.

Claims (7)

1. A method for reducing muscle atrophy in limbs in a subject having muscle atrophy due to muscle inactivation caused by nerve injury, comprising administering to the subject at least one of the group consisting of isolated astaxanthin and an ester thereof as an effective ingredient, thereby increasing muscle weight.

2. The method according to claim 1 , wherein the at least one of the group consisting of astaxanthin and an ester thereof is administered as an effective ingredient in the form of a food or a drink.

3. The method of claim 1 , wherein the administration is oral.

4. The method of claim 1 , wherein reducing muscle atrophy comprises improving gene expression.

5. The method of claim 1 , wherein the nerve injury is due to denervation.

6. The method of claim 5 , wherein the denervation is due to severing of the nerve.

7. The method of claim 5 , wherein the denervation is due to cutting the nerve.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042434 FRAME: 0705. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Oct 23, 2017
From: FUJI CHEMICAL INDUSTRY CO., LTD.
To: FUJI CHEMICAL INDUSTRIES CO., LTD.
Reel/Frame 044745/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2017
From: NAITO, YUJI
To: FUJI CHEMICAL INDUSTRIES CO., LTD.
Reel/Frame 043926/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2017
From: TAKAHASHI, JIRO; AOI, WATARU
To: FUJI CHEMICAL INDUSTRY CO., LTD.
Reel/Frame 042224/0404 →
CHANGE OF NAME Recorded May 3, 2017
From: FUJI CHEMICAL INDUSTRY CO., LTD.
To: FUJI CHEMICAL INDUSTRIES CO., LTD.
Reel/Frame 042434/0705 →
Priority Claims (1)
JP 2004-028698 · Feb 4, 2004 · national
Continuity (4)
Continuation 12155914 · Jun 11, 2008
Division 11498725 · Aug 4, 2006
Continuation PCTJP2005001718 · Feb 4, 2005
Related Publication 20150057365A1 · Feb 26, 2015